Abstract 67P
Background
Bioplatin is an oral, nanoplatinum-based compound manufactured using patented innovative processing, based on green technology. The anticancer and cancer-preventive properties of Bioplatin, a new oral platinum-based experimental medication, were assessed in prostate cancer xenografts using Severe Combined Immunodeficiency mice (SCID).
Methods
Twenty-one SCID mice were divided into 4 groups: 3 received Bioplatin at doses of 500, 1000, and 2000 mg/kg body weight, and one was a vehicle control. Prostate cancer cells were subcutaneously implanted into each mouse after four weeks of dosage administration. Tumor growth was observed for six weeks to evaluate Bioplatin’s preventive potential based on tumor volume, inhibition, growth delay, weight, and histology.
Results
Tumor development was absent in 2 mice from the high-dose group and one from the mid-dose group, while low-dose and vehicle control groups developed tumors. Mice in the mid (4/5) and high (4/6) dosage groups that did not acquire tumors were labeled as “No Takes”. The Bioplatin-treated groups had smaller tumor volumes than the vehicle control group, indicating inhibited and delayed tumor growth. Gross pathology, body weight, bone marrow, and clinical symptoms showed no apparent alterations. Histopathological analysis revealed increased apoptosis and pyknosis in all treatment groups, with the highest levels in the high-dose group. Neoplastic cell proliferation was lowest in the mid and high-dose groups, moderate in the low dose group, and highest in the vehicle control. Necrosis scores were marginally greater in the mid and high-dose groups. The myeloid to erythroid ratio did not show any suppression of bone marrow due to Bioplatin.
Conclusions
Findings suggest that oral administration of Bioplatin holds promise as an effective anticancer and cancer-preventive agent for secondary prevention, potentially increasing progression or disease-free survival. The observed effects are probably due to direct cytotoxicity or interactions with innate immune components, as SCID mice lack adaptive immunity. Further investigation is warranted to understand the exact mechanism of action or involvement of any immunological pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y. Bendale: Financial Interests, Personal and Institutional, Ownership Interest: Rasayani Biologics. D.A. Kadam: Financial Interests, Institutional, Full or part-time Employment: Rasayani Biologics. All other authors have declared no conflicts of interest.